Full-Time

Senior Scientist

Molecular Bioanalytics

Posted on 8/13/2024

Editas Medicine

Editas Medicine

201-500 employees

Develops gene editing treatments using CRISPR

No salary listed

Mid, Senior

Cambridge, MA, USA

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Requirements
  • PhD in pharmaceutics, medicinal chemistry, analytical chemistry, DMPK or a relevant discipline, with a minimum of 3 years of drug discovery experience; Bachelor’s/Master’s degrees with extensive and relevant industry experience will also be considered.
  • Extensive knowledge and experience in conducting quantitative bioanalysis using molecular bioanalytical techniques such as qPCR, ddPCR to support discovery and development projects.
  • Demonstrated knowledge and experience in establishing bioanalytical methods, ADME, PK/PD for a variety of therapeutic modalities, ideally in preclinical environment.
  • Experience in leading and developing strong, technical, delivery-focused teams is a plus.
  • Experience with gene editing or gene delivery technologies and lipid nanoparticle delivery is highly desired.
  • Excellent communication skills and proven ability to collaborate with interdisciplinary teams, along with exceptional scientific thinking and problem-solving skills.
  • Ability to multi-task to meet research and development goals in a fast-paced environment.
Responsibilities
  • Establishing and executing on routine workflows for method development using techniques such as molecular bioanalytical assays (qPCR, ddPCR) to support quantitative bioanalysis and apply innovative solutions to solve complex problems to advance the pipeline.
  • Develop and execute PCR-based methods, sample analysis, data generation, and report writing for preclinical and clinical samples.
  • Develop nucleic acid extraction (DNA/RNA) and quantification from a broad-spectrum animal tissues.
  • Responsible for the design and execution of in vitro and in vivo studies to address ADME questions aligned with our overall scientific strategy.
  • Execute bioanalytical assay development strategies to characterize ADME, PK and biodistribution properties of the drug product and address key scientific questions.
  • Ensure that the data obtained is of the highest quality, and stage appropriate.
  • Write bioanalytical assay protocols and reports that are suitable for inclusion in registration dossiers.
  • Contribute effectively to patents, reports, and publications of scientific findings.
  • Model behaviors of a strong leader and mentor to staff members as appropriate.
  • Establish strong partnerships across sites and across functions; Work cross-functionally within the R&D organization.
  • Ensure compliance with electronic notebooks (ELN), high data integrity and company policies.

Editas Medicine focuses on gene editing using CRISPR technology, which allows for precise modifications to DNA in cells. This technique has the potential to correct genetic defects that lead to various diseases. The company is engaged in the entire process of drug development, from discovering new treatments to manufacturing and bringing them to market. Editas Medicine aims to create effective and lasting therapies that can enhance the quality of life for patients suffering from serious health conditions. Unlike many competitors, Editas Medicine has a diverse pipeline of experimental medicines and actively shares clinical data to engage with the medical community. Their goal is to provide transformative treatments for patients worldwide.

Company Size

201-500

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • In-vivo gene editing shows promise in treating blood-forming stem cells and liver diseases.
  • $50+ million financing supports strategic pivot towards innovative gene editing projects.
  • Collaboration with Genevant accelerates development of novel gene editing treatments.

What critics are saying

  • Executive turnover may affect financial strategy and investor confidence.
  • 65% workforce reduction could delay development timelines and impact morale.
  • Failure to secure sickle cell partner indicates challenges in collaboration and market positioning.

What makes Editas Medicine unique

  • Editas Medicine focuses on in-vivo gene editing for stem cells and liver diseases.
  • The company leverages CRISPR technology for precise DNA editing in therapeutic development.
  • Editas collaborates with Genevant Sciences to enhance mRNA-LNP gene editing therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Tuition Reimbursement

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Plan

Wellness Program

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

6%

2 year growth

0%
BioSpace
Mar 28th, 2025
Editas Medicine Announces Chief Financial Officer Transition

Amy Parsion Senior Vice President of Finance Amy Parison Appointed CFOErick J. Lucera to Step Down as CFO to pursue another opportunitySenior Vice President of Finance Amy Parison Appointed CFOCAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer.“We are thrilled to promote Amy to the executive leadership team as our new CFO

BioSpace
Mar 21st, 2025
Dyne Therapeutics Announces Appointment Of Erick J. Lucera As Chief Financial Officer

Erick J. Lucera Erick J. Lucera, Chief Financial Officer (CFO) of Dyne Therapeutics- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointment of Erick J. Lucera, as chief financial officer (CFO) of Dyne, effective March 31, 2025. Mr

Investing.com
Mar 20th, 2025
Editas Medicine appoints new CFO amid executive reshuffle

Following Lucera's departure, Editas has appointed Amy Parison, the current Senior Vice President of Finance, as the new Senior Vice President, Chief Financial Officer, and Treasurer.

Stock Titan
Feb 24th, 2025
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Editas Medicine (NASDAQ: EDIT) has announced it will release its Q4 and Full Year 2024 financial results and business updates on March 5, 2025, through a press release and SEC filings.

The Economic Times
Dec 14th, 2024
Editas Medicine to reduce about 65% of its workforce over the next six months

Editas is shifting focus to developing in-vivo treatments that edit stem cells inside the human body after recent pre-clinical data showed promise in blood-forming stem cells and the liver, and plans to share data and development timelines in the first quarter of 2025.

INACTIVE